The trial will compare the clinical results of DVT patients treated with the ClotTriever System versus anticoagulation. Credit: Bencemor / Shutterstock.com.

Inari Medical has enrolled the first participant in the DEFIANCE trial of its ClotTriever System in iliofemoral deep vein thrombosis (DVT) patients.

Allegheny Health Network interventional radiologist Dr Abdullah Shaikh has enrolled the first participant in the trial in Pittsburgh, Pennsylvania, US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The prospective randomised controlled trial (RCT) has been designed to compare the clinical results of DVT patients treated with the ClotTriever System versus treatment with anticoagulation only.

Up to 300 DVT patients are expected to be enrolled at up to 60 centres across the world.

Inari Medical chief medical officer Dr Thomas Tu said: “With six major clinical studies, including two ongoing RCTs, Inari is wholly committed to VTE patients and producing definitive evidence to support our technologies.

See Also:

“None of this is possible without the collaboration and dedication of our clinical trial investigators who continually push the field forward in the name of better patient outcomes.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The ClotTriever is an over-the-wire system that is designed to capture and remove large clot burdens from big vessels.

It is developed to eliminate the need for thrombolytics and avoid capital equipment.

The company stated that the DEFIANCE trial is its second RCT and it will be enrolling participants in the PEERLESS pulmonary embolism trial simultaneously.

MedStar Health Vascular Surgery chair Dr Steven Abramowitz said: “DEFIANCE is an important step forward and will answer critical questions about how we manage DVT patients.

“Prior RCTs have focused on thrombolytic-based interventions, which have known downsides and limited effectiveness.

“This ClotTriever RCT is the first to compare lytic-free thrombectomy to anticoagulation for DVT.”